Sign up
Log in
These Mid-Cap Stocks Outshone The Market Volatility Last Week (Apr 7-Apr 11): Are These In Your Portfolio?
Share
Listen to the news

These mid-cap stocks were the best performers in the last week. Are they in your portfolio?

  1. Agilon Health (NYSE:AGL) shares jumped 36.87%. Bernstein analyst Amir Farahan upgraded the company from Market Perform to Outperform and raised the price forecast from $3.3 to $8.5.
  2. Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stock escalated 35.85% after the U.S. Food and Drug Administration news about animal testing.
  3. Certara Inc. (NASDAQ:CERT) stock upped 35.18%. The U.S. Food and Drug Administration announced a major shift in evaluating monoclonal antibody therapies and other drugs, emphasizing a transition from traditional animal testing.
  4. AeroVironment, Inc. (NASDAQ:AVAV) shares increased 31.06%, probably following President Trump’s decision to implement a 90-day pause on reciprocal tariffs for all countries except China.
  5. Sterling Infrastructure (NYSE:STRL) shares increased by 30.61%, probably following President Trump’s decision to implement a 90-day pause on reciprocal tariffs for all countries except China.
  6. Orla Mining Ltd. (AMEX:ORLA) shares rose 29.35%.
  7. Iamgold Corporation (NYSE:IAG) shares were up 28.24%, probably as gold and silver gained amid macro uncertainty.
  8. Sibanye Stillwater (NYSE:SBSW) shares were up 27.33% last week as gold and silver gained amid macro uncertainty.
  9. Loar Holdings Inc. (NYSE:LOAR) stock upped 27.20%.
  10. Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) shares gained 26.84% after the company announced that the Phase 3 TRANSCEND trial met its primary endpoint. Multiple analysts raised their price targets on the stock.
  11. Telix Pharmaceuticals Limited (NASDAQ:TLX) stock surged 22.34%. The company selected Cardinal Health to distribute Gozellix, a PSMA-PET imaging agent for prostate cancer, across the U.S.

Photo via Shutterstock

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.